Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.
Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy. On March 27, 2020, durvalumab was approved by the FDA for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Durvalumab is indicated for the treatment of adults with the following conditions:
The Miriam Hospital, Providence, Rhode Island, United States
Rhode Island Hospital, Providence, Rhode Island, United States
Samsung Medical Center, Seoul, MA, Korea, Republic of
M D Anderson Cancer Center, Houston, Texas, United States
Seoul National University Hospital, Seoul, Korea, Republic of
Seoul National University Hospital, Seoul, Korea, Republic of
Institut Paoli Calmettes, Marseille, France
Centre Eugène Marquis, Rennes, France
Groupe Hospitalier Pitié-Salpetrière, Paris, France
University of Kansas Cancer Center, Westwood, Kansas, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Clinica IMQ Zorrotzaurre, Bilbao, Spain
ICO Badalona, Badalona, Barcelona, Spain
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
University Of Alabama At Birmingham, Birmingham, Alabama, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Medical University of South Carolina - Hollings Cancer Center, Charleston, South Carolina, United States
Research Site, Ho Chi Minh, Vietnam
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.